bunazosin has been researched along with Chronic Disease in 3 studies
bunazosin: structure
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study the effect of bunazosin on exercise capacity in patients with congestive heart failure (NYHA II-III), anaerobic thresholds (AT, VO2, ml/min/kg) were measured before (control) and after initial 1 = 2mg administration of bunazosin (acute phase; N = 14) and after two weeks of bunazosin therapy (3mg/day, 1mg t." | 7.68 | [The acute and chronic effects of bunazosin on exercise capacity estimated by the anaerobic threshold in patients with chronic congestive heart failure]. ( Hosoda, S; Kaneko, N; Kawagoe, Y; Kimata, S; Kimura, H; Konno, K; Miki, N; Nagashima, H; Sumiyoshi, T, 1992) |
| "The acute hemodynamic effect (right atrial pressure, mean pulmonary artery pressure, pulmonary capillary wedge pressure, cardiac index, heart rate, blood pressure) and neurohumoral response (alpha-ANP, plasma renin activity, aldosterone, angiotensin II) of Bunazosin, oral alpha 1 blocker, was investigated in 28 patients with congestive heart failure at rest and immediately after exercise." | 7.67 | [Acute and chronic effects of bunazosin in patients with congestive heart failure]. ( Hasegawa, K; Inoue, S; Kawahara, Y; Nezuo, S; Sawayama, T; Tadaoka, S, 1989) |
| "To determine whether bunazosin (alpha 1-adrenoceptor blocking agent) can alter the hemodynamic profile of chronic heart failure secondary to myocardial infarction, the drug was administered to Wistar rats 4 weeks after coronary ligation, and continued for 4 weeks." | 7.67 | Hemodynamic benefits of long-term bunazosin (alpha-1 blocker) therapy in rats with myocardial infarction and heart failure. ( Fukuta, S; Itagaki, T; Kusukawa, R; Toma, Y; Umemoto, S; Yamakawa, K; Yoshinaga, T, 1989) |
| "To study the effect of bunazosin on exercise capacity in patients with congestive heart failure (NYHA II-III), anaerobic thresholds (AT, VO2, ml/min/kg) were measured before (control) and after initial 1 = 2mg administration of bunazosin (acute phase; N = 14) and after two weeks of bunazosin therapy (3mg/day, 1mg t." | 3.68 | [The acute and chronic effects of bunazosin on exercise capacity estimated by the anaerobic threshold in patients with chronic congestive heart failure]. ( Hosoda, S; Kaneko, N; Kawagoe, Y; Kimata, S; Kimura, H; Konno, K; Miki, N; Nagashima, H; Sumiyoshi, T, 1992) |
| "The acute hemodynamic effect (right atrial pressure, mean pulmonary artery pressure, pulmonary capillary wedge pressure, cardiac index, heart rate, blood pressure) and neurohumoral response (alpha-ANP, plasma renin activity, aldosterone, angiotensin II) of Bunazosin, oral alpha 1 blocker, was investigated in 28 patients with congestive heart failure at rest and immediately after exercise." | 3.67 | [Acute and chronic effects of bunazosin in patients with congestive heart failure]. ( Hasegawa, K; Inoue, S; Kawahara, Y; Nezuo, S; Sawayama, T; Tadaoka, S, 1989) |
| "To determine whether bunazosin (alpha 1-adrenoceptor blocking agent) can alter the hemodynamic profile of chronic heart failure secondary to myocardial infarction, the drug was administered to Wistar rats 4 weeks after coronary ligation, and continued for 4 weeks." | 3.67 | Hemodynamic benefits of long-term bunazosin (alpha-1 blocker) therapy in rats with myocardial infarction and heart failure. ( Fukuta, S; Itagaki, T; Kusukawa, R; Toma, Y; Umemoto, S; Yamakawa, K; Yoshinaga, T, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kawagoe, Y | 1 |
| Kimura, H | 1 |
| Kaneko, N | 1 |
| Sumiyoshi, T | 1 |
| Nagashima, H | 1 |
| Kimata, S | 1 |
| Hosoda, S | 1 |
| Konno, K | 1 |
| Miki, N | 1 |
| Kawahara, Y | 1 |
| Hasegawa, K | 1 |
| Sawayama, T | 1 |
| Nezuo, S | 1 |
| Inoue, S | 1 |
| Tadaoka, S | 1 |
| Itagaki, T | 1 |
| Toma, Y | 1 |
| Umemoto, S | 1 |
| Yamakawa, K | 1 |
| Yoshinaga, T | 1 |
| Fukuta, S | 1 |
| Kusukawa, R | 1 |
3 other studies available for bunazosin and Chronic Disease
| Article | Year |
|---|---|
[The acute and chronic effects of bunazosin on exercise capacity estimated by the anaerobic threshold in patients with chronic congestive heart failure].
Topics: Adult; Aged; Anaerobic Threshold; Chronic Disease; Exercise Test; Exercise Tolerance; Female; Heart | 1992 |
[Acute and chronic effects of bunazosin in patients with congestive heart failure].
Topics: Adrenergic alpha-Antagonists; Atrial Natriuretic Factor; Chronic Disease; Exercise Test; Female; Hea | 1989 |
Hemodynamic benefits of long-term bunazosin (alpha-1 blocker) therapy in rats with myocardial infarction and heart failure.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Cardiac Output, Low; Chronic Disease; Female; | 1989 |